Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

VirRx Inc
Profile last edited on: 12/6/2010      CAGE: 42YT7      UEI: TFAJUKY8A1C1

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
1999
First Award
1999
Latest Award
2009
Program Status
Inactive
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

1609 Adgers Wharf Drive
St. Louis, MO 63017
   (314) 977-8857
   info@virrx.com
   www.virrx.com
Location: Single
Congr. District: 02
County: St. Louis

Public Profile

VirRx, Inc., is a biotechnology company with a primary interest in cancer gene therapy. Its broad mission is to develop genetically modified "smart bomb" adenoviruses for use in treating human cancers. Adenoviruses are ubiquitous, benign viruses that are one of the causes of the common cold

Extent of SBIR involvement

User Avatar
Phase I Awards
8
Phase II Awards
1
Conversion Rate
12.50%
Phase I Dollars
$1,485,424
Phase II Dollars
$711,039
Total Awarded
$2,196,463

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2009 1 NIH $260,910
Project Title: An Hbv Polymerase Rna Binding Assay Suitable For Inhibitor Screening
2007 1 NIH $222,658
Project Title: Syrian Hamster as a Permissive Model for Testing Anti-Adenovirus Drugs
2004 1 NIH $182,459
Project Title: Animal Model for Adenovirus Oncolytic Vectors
2004 1 NIH $247,645
Project Title: Anti-Cancer Vectors that Express TRAIL
2004 1 NIH $161,875
Project Title: Regulatable expression of TRAIL and viral oncolysis

Key People / Management

  William S Wold -- President

  Feng Cao

  Konstantin Doronin

  Michael H Green

  Peter Krajcsi

Company News

There are no news available.